i need you to adapt the OASIS Data use agreement with mine dataset.

this is mine dataset:
Date of publication xxxx 00, 0000, date of current version xxxx 00, 0000.
Digital Object Identifier 10.1109/ACCESS.2024.0429000
NeuroSense: A Novel EEG Dataset Utilizing
Low-Cost, Sparse Electrode Devices for Emotion
Exploration
Tommaso Colafiglio1,2, Angela Lombardi2, Paolo Sorino2, Elvira Brattico3,4, Domenico Lofù2,
Danilo Danese2, Eugenio Di Sciascio2, Tommaso Di Noia2, and Fedelucio Narducci2,

this is the ABSTRACT Emotion recognition is crucial in affective computing, aiming to bridge the gap between
human emotional states and computer understanding. This study presents NeuroSense, a novel electroen-
cephalography (EEG) dataset utilizing low-cost, sparse electrode devices for emotion exploration. Our
dataset comprises EEG signals collected with the portable 4-electrodes device Muse 2 from 30 participants
who, thanks to a neurofeedback setting, watch 40 music videos and assess their emotional responses. These
assessments use standardized scales gauging arousal, valence, and dominance. Additionally, participants
rate their liking for and familiarity with the videos. We develop a comprehensive preprocessing pipeline and
employ machine learning algorithms to translate EEG data into meaningful insights about emotional states.
We verify the performance of machine learning (ML) models using the NeuroSense dataset. Despite utilizing
just 4 electrodes, our models achieve an average accuracy ranging from 75% to 80% across the four quadrants
of the dimensional model of emotions. We perform statistical analyses to assess the reliability of the self-
reported labels and the classification performance for each participant, identifying potential discrepancies
and their implications. We also compare our results with those obtained using other public EEG datasets,
highlighting the advantages and limitations of sparse electrode setups in emotion recognition. Our results
demonstrate the potential of low-cost EEG devices in emotion recognition, highlighting the effectiveness of
ML models in capturing the dynamic nature of emotions. The NeuroSense dataset is publicly available,
inviting further research and application in human-computer interaction, mental health monitoring, and
beyond


this is the reference Data use agreement:

Request Access to All OASIS Datasets
OASIS Data Use Agreement

The OASIS data are distributed to the greater scientific community under the following terms:

    User will not use the OASIS datasets, either alone or in concert with any other information, to make any effort to identify or contact individuals who are or may be the sources of the information in the dataset. If User inadvertently receives identifiable information or otherwise identifies a subject, User will promptly notify OASIS and follow OASIS’s reasonable written instructions, which may include the return or destruction of identifiable information.
    User is strictly prohibited from generating or using images or comparable representations of the face, head, or body for facial recognition, re-identification, or other purposes that could allow the identities of research participants to be readily ascertained.
    User will not use or further disclose the OASIS-3 or OASIS-4 other than as permitted by this agreement or as otherwise required by law. Additionally, User will not use or further disclose any derivative works or derivative data of the OASIS datasets, in any case in whole or in part, that could be used to reconstruct a facial image. User shall report to OASIS promptly upon User’s discovery of any unauthorized use or disclosure not permitted by this License. User shall provide the following information: (1) the nature of the use or disclosure; (2) the information used or disclosed; (3) the identity of the persons and/or entities that made the use or disclosure; and (4) what corrective action will be taken by User as a result of the use or disclosure. User shall take any other reasonable actions available to it to mitigate any detrimental effects of the use or disclosure.
    User will acknowledge the use of OASIS data and data derived from OASIS data when publicly presenting any results or algorithms that benefitted from their use. Papers, book chapters, books, posters, oral presentations, and all other printed and digital presentations of results derived from OASIS data should contain the following:
        Acknowledgments: “Data were provided [in part] by OASIS [insert appropriate OASIS source info]”
            OASIS-1: Cross-Sectional: Principal Investigators: D. Marcus, R, Buckner, J, Csernansky J. Morris; P50 AG05681, P01 AG03991, P01 AG026276, R01 AG021910, P20 MH071616, U24 RR021382
            OASIS-2: Longitudinal: Principal Investigators: D. Marcus, R, Buckner, J. Csernansky, J. Morris; P50 AG05681, P01 AG03991, P01 AG026276, R01 AG021910, P20 MH071616, U24 RR021382
            OASIS-3: Longitudinal Multimodal Neuroimaging: Principal Investigators: T. Benzinger, D. Marcus, J. Morris; NIH P30 AG066444, P50 AG00561, P30 NS09857781, P01 AG026276, P01 AG003991, R01 AG043434, UL1 TR000448, R01 EB009352. AV-45 doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly.
            OASIS-3_AV1451: Principal Investigators: T. Benzinger, J. Morris; NIH P30 AG066444, AW00006993. AV-1451 doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly.
            OASIS-4: Clinical Cohort: Principal Investigators: T. Benzinger, L. Koenig, P. LaMontagne
        Citation: The specific publications that are appropriate to cite in any given study will depend on what OASIS data were used and for what purposes. An annotated and current list of OASIS publications is available at http://www.oasis-brains.org.
            OASIS-1: Cross-Sectional: https://doi.org/10.1162/jocn.2007.19.9.1498
            OASIS-2: Longitudinal: https://doi.org/10.1162/jocn.2009.21407
            OASIS-3: Longitudinal Multimodal Neuroimaging: https://doi.org/10.1101/2019.12.13.19014902
            OASIS-4: Clinical Cohort: https://doi.org/10.1016/j.nicl.2020.102248
    All proposed publications or presentations using Florbetapir F18 (AV45) or Flortaucipir F18 (AV1451) PET data must be submitted to Avid Radiopharmaceuticals for review and comment thirty days prior to such presentation or publication for review of intellectual property interests. See Imaging data dictionary for contact information and details.
    User agree to provide the Knight ADRC upon request with information on your use of OASIS data
    Failure to abide by these data use terms may result in termination of your right to access and use OASIS data.

Who Can Obtain Access?

By submitting the data request I am agreeing to abide by the terms of this data use Agreement.